Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.87 Million SEK | -84.56% |
| 2022 | 25.09 Million SEK | 51.07% |
| 2021 | 16.61 Million SEK | -2.33% |
| 2020 | 17 Million SEK | 133.81% |
| 2019 | 7.27 Million SEK | -45.51% |
| 2018 | 13.35 Million SEK | 644.98% |
| 2017 | 1.79 Million SEK | -89.0% |
| 2016 | 16.28 Million SEK | 24.08% |
| 2015 | 13.12 Million SEK | 4.54% |
| 2014 | 12.55 Million SEK | -46.66% |
| 2013 | 23.54 Million SEK | 116.43% |
| 2012 | 10.87 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | - SEK | -100.0% |
| 2024 Q1 | 2.63 Million SEK | -32.02% |
| 2024 Q2 | 2.39 Million SEK | -8.93% |
| 2023 Q3 | 16.84 Million SEK | -8.88% |
| 2023 FY | 3.87 Million SEK | -84.56% |
| 2023 Q2 | 18.48 Million SEK | 201.66% |
| 2023 Q1 | 6.12 Million SEK | -75.58% |
| 2023 Q4 | 3.87 Million SEK | -77.0% |
| 2022 Q4 | 25.09 Million SEK | 31.04% |
| 2022 Q3 | 19.14 Million SEK | 27.04% |
| 2022 FY | 25.09 Million SEK | 51.07% |
| 2022 Q1 | 8.01 Million SEK | -51.72% |
| 2022 Q2 | 15.07 Million SEK | 87.95% |
| 2021 Q4 | 16.61 Million SEK | -14.53% |
| 2021 Q1 | 15.09 Million SEK | -11.27% |
| 2021 Q2 | 18.28 Million SEK | 21.16% |
| 2021 Q3 | 19.43 Million SEK | 6.29% |
| 2021 FY | 16.61 Million SEK | -2.33% |
| 2020 FY | 17 Million SEK | 133.81% |
| 2020 Q4 | 17 Million SEK | 7.71% |
| 2020 Q3 | 15.78 Million SEK | 40.55% |
| 2020 Q1 | 14.4 Million SEK | 98.03% |
| 2020 Q2 | 11.23 Million SEK | -22.01% |
| 2019 Q4 | 7.27 Million SEK | 24.88% |
| 2019 Q1 | 8.96 Million SEK | -32.87% |
| 2019 FY | 7.27 Million SEK | -45.51% |
| 2019 Q3 | 5.82 Million SEK | -68.23% |
| 2019 Q2 | 18.33 Million SEK | 104.61% |
| 2018 Q2 | 14.39 Million SEK | 369.79% |
| 2018 Q3 | 11.81 Million SEK | -17.96% |
| 2018 Q4 | 13.35 Million SEK | 13.01% |
| 2018 FY | 13.35 Million SEK | 644.98% |
| 2018 Q1 | 3.06 Million SEK | 71.04% |
| 2017 Q4 | 1.79 Million SEK | -82.04% |
| 2017 FY | 1.79 Million SEK | -89.0% |
| 2017 Q3 | 9.98 Million SEK | 5.42% |
| 2017 Q2 | 9.46 Million SEK | -43.77% |
| 2017 Q1 | 16.83 Million SEK | 3.36% |
| 2016 Q2 | 16.34 Million SEK | 0.0% |
| 2016 Q4 | 16.28 Million SEK | -16.62% |
| 2016 FY | 16.28 Million SEK | 24.08% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q3 | 19.53 Million SEK | 19.49% |
| 2015 Q1 | 10.95 Million SEK | -12.77% |
| 2015 FY | 13.12 Million SEK | 4.54% |
| 2015 Q4 | 13.12 Million SEK | -22.03% |
| 2015 Q3 | 16.83 Million SEK | 44.08% |
| 2015 Q2 | 11.68 Million SEK | 6.68% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q3 | 12.24 Million SEK | 0.0% |
| 2014 Q4 | 12.55 Million SEK | 2.54% |
| 2014 FY | 12.55 Million SEK | -46.66% |
| 2013 Q4 | 23.54 Million SEK | 0.0% |
| 2013 FY | 23.54 Million SEK | 116.43% |
| 2012 FY | 10.87 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.76% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.76% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 98.338% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.791% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 97.668% |
| CellaVision AB (publ) | 64.7 Million SEK | 94.014% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -753.084% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -115.167% |
| Duearity AB (publ) | 10.58 Million SEK | 63.4% |
| Dignitana AB (publ) | 19.1 Million SEK | 79.727% |
| Episurf Medical AB (publ) | 5.2 Million SEK | 25.519% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.952% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | 53.052% |
| Iconovo AB (publ) | 7.72 Million SEK | 49.863% |
| Integrum AB (publ) | 6.42 Million SEK | 39.712% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -1779.878% |
| Mentice AB (publ) | 9.55 Million SEK | 59.475% |
| OssDsign AB (publ) | 3.15 Million SEK | -22.952% |
| Paxman AB (publ) | 13.57 Million SEK | 71.459% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 81.318% |
| SciBase Holding AB (publ) | 6.79 Million SEK | 43.019% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 87.816% |
| Sedana Medical AB (publ) | 4.3 Million SEK | 10.056% |
| Senzime AB (publ) | 11.46 Million SEK | 66.228% |
| SpectraCure AB (publ) | 6.71 Million SEK | 42.34% |
| Stille AB | 62.94 Million SEK | 93.847% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.815% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 87.68% |